European Urology

A second publication from the ARCHES trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT04736199 with the most citations, so it is the natural first reading for anyone following the ARANOTE trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

The standard-of-care entries on the penile cancer pages, from keeping as much of the penis as is safe to staging the groins with a sentinel node procedure, follow this guideline.

Most of the decisions on a non-muscle-invasive bladder cancer page (single instillation, BCG maintenance, early cystectomy, bladder-sparing trials) follow this guideline or its American counterpart.

This is the paper Europe PMC returns for registry id NCT02861573 with the most citations, so it is the natural first reading for anyone following the KEYNOTE-365 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

Kidney cancer subtype pages use these definitions; several rare entities are now diagnosed by molecular testing rather than appearance alone.

One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

The limit of what a prostate scan can be asked to do. It is a good triage test for whether to biopsy and a poor map of where every tumour is, which matters for anyone being offered treatment to part of the gland or follow-up by imaging alone.

One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

It is the reason a prostate cancer fusion frequency quoted without an ancestry is unsafe. In this cohort the founder event that defines almost half of Western tumours is uncommon, and the fusion-negative, CHD1-deleted route dominates instead.

It made PTEN a protein test rather than a genomic one in this disease, and the concordance between early and late biopsies is the practical point: the diagnostic block usually answers the question, so a fresh biopsy is not needed to make this call.

The honest state of the overdiagnosis question. Prostate cancer is common in the prostates of men who die of something else, screening finds a proportion of it, and how much of that is harm depends on what is done next. The fix is not a better estimate but fewer treatments for the cancers that do not need them.

The risk groups that decide whether a patient gets a single chemotherapy instillation, BCG, or early cystectomy trace back to this work. Later models (CUETO, the 2021 EAU risk groups) refine the estimates for BCG-treated patients.

A second publication from the ARCHES trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT04736199 with the most citations, so it is the natural first reading for anyone following the ARANOTE trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

The standard-of-care entries on the penile cancer pages, from keeping as much of the penis as is safe to staging the groins with a sentinel node procedure, follow this guideline.

Most of the decisions on a non-muscle-invasive bladder cancer page (single instillation, BCG maintenance, early cystectomy, bladder-sparing trials) follow this guideline or its American counterpart.

This is the paper Europe PMC returns for registry id NCT02861573 with the most citations, so it is the natural first reading for anyone following the KEYNOTE-365 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

Kidney cancer subtype pages use these definitions; several rare entities are now diagnosed by molecular testing rather than appearance alone.

One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

The limit of what a prostate scan can be asked to do. It is a good triage test for whether to biopsy and a poor map of where every tumour is, which matters for anyone being offered treatment to part of the gland or follow-up by imaging alone.